245 related articles for article (PubMed ID: 19521340)
21. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
23. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
24. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
25. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
26. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
27. The long and the short of it: the MDM4 tail so far.
Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
[TBL] [Abstract][Full Text] [Related]
28. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
29. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.
Marine JC; Francoz S; Maetens M; Wahl G; Toledo F; Lozano G
Cell Death Differ; 2006 Jun; 13(6):927-34. PubMed ID: 16543935
[No Abstract] [Full Text] [Related]
30. The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.
Tembe V; Martino-Echarri E; Marzec KA; Mok MT; Brodie KM; Mills K; Lei Y; DeFazio A; Rizos H; Kettle E; Boadle R; Henderson BR
Cell Signal; 2015 Sep; 27(9):1763-71. PubMed ID: 26022179
[TBL] [Abstract][Full Text] [Related]
31. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
32. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
33. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
[TBL] [Abstract][Full Text] [Related]
34. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
35. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
36. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.
Migliorini D; Lazzerini Denchi E; Danovi D; Jochemsen A; Capillo M; Gobbi A; Helin K; Pelicci PG; Marine JC
Mol Cell Biol; 2002 Aug; 22(15):5527-38. PubMed ID: 12101245
[TBL] [Abstract][Full Text] [Related]
37. MDM4 expression in fibrolamellar hepatocellular carcinoma.
Karki A; Putra J; Kim SS; Laquaglia MJ; Perez-Atayde AR; Sadri-Vakili G; Vakili K
Oncol Rep; 2019 Oct; 42(4):1487-1496. PubMed ID: 31322272
[TBL] [Abstract][Full Text] [Related]
38. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
39. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.
Luu Y; Bush J; Cheung KJ; Li G
Exp Cell Res; 2002 Jun; 276(2):214-22. PubMed ID: 12027451
[TBL] [Abstract][Full Text] [Related]
40. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]